Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.87 USD | +2.39% | +25.36% | 0.00% |
May. 14 | Kyverna Therapeutics Q1 Loss Narrows | MT |
Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
Financials (USD)
Sales 2024 * | 15M | Sales 2025 * | 10M | Capitalization | 668M |
---|---|---|---|---|---|
Net income 2024 * | -140M | Net income 2025 * | -194M | EV / Sales 2024 * | 31.4 x |
Net cash position 2024 * | 197M | Net cash position 2025 * | 142M | EV / Sales 2025 * | 52.6 x |
P/E ratio 2024 * |
-4.25
x | P/E ratio 2025 * |
-3.75
x | Employees | 96 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.27% |
1 day | +2.39% | ||
1 week | +25.36% | ||
Current month | +4.82% | ||
1 month | -30.67% | ||
3 months | -46.66% |
Managers | Title | Age | Since |
---|---|---|---|
Peter Maag
CEO | Chief Executive Officer | 56 | 22-10-12 |
Ryan Jones
DFI | Director of Finance/CFO | 36 | 17-12-31 |
Dominic Borie
CTO | Chief Tech/Sci/R&D Officer | 61 | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 18-08-31 |
Ian Clark
CHM | Chairman | 62 | 21-09-14 |
Dan Spiegelman
BRD | Director/Board Member | 65 | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 15.87 | +2.39% | 497,255 |
24-05-14 | 15.5 | +5.95% | 337,700 |
24-05-13 | 14.63 | +4.50% | 480,075 |
24-05-10 | 14 | -4.11% | 217,579 |
24-05-09 | 14.6 | +15.32% | 280,449 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 668M | |
+29.77% | 49.18B | |
+1.00% | 42.11B | |
+50.47% | 40.37B | |
-5.26% | 28.85B | |
+13.68% | 26.09B | |
-22.99% | 18.71B | |
+8.22% | 13.26B | |
+32.41% | 12.32B | |
-1.62% | 11.99B |
- Stock Market
- Equities
- KYTX Stock